Novel Immunogenic Therapy for Prostate Cancer

Background

One of the major problems for patients with prostate cancer is the re-emergency of androgen independent cancer after surgical removal or radioablation of the tumors; the re-emergent cancer is refractive to chemotherapy that target immune checkpoints. It was previously discovered by UC San Diego researchers that B cells were involved in assist in the re-emergence of the tumor. By removing the B cell population, re-emergence of prostate cancer would be significantly delayed (for more details please see Case 2009-172).

Technology Description

Normally patients with prostate cancer does not respond to an immunogenic low dose of oxaliplatin. The same above-mentioned UC San Diego researchers have found a way to sensitize prostate cancer to low-dose oxaliplatin by targeting a certain signaling pathway and achieve nearly complete tumor elimination.

Related Materials

• Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. (2010) B-Cell-Derived Lymphotoxin Promotes Castration-Resistant Prostate Cancer. Nature; 464(7286):302-5. - 03/11/2010

Patent Status